论文部分内容阅读
目的探讨吉非替尼或吉西他滨联合卡铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法将137例晚期NSCLC患者随机分为两组,试验组71例,给予吉非替尼联合卡铂治疗;对照组66例,给予吉西他滨联合卡铂治疗。对两组患者的治疗效果和生存质量进行评价,并统计不良反应发生情况。结果试验组和对照组NSCLC患者的总有效率分别为76.1%和47.0%,差异有统计学意义(P<0.05),疾病控制率分别为87.3%和78.8%(P>0.05)。试验组患者的中位生存期为14.5个月,与对照组患者(11.8个月)比较,差异有统计学意义(P<0.05)。试验组患者的不良反应主要为痤疮样皮疹、腹泻、恶心、呕吐以及食欲不振,对照组患者主要为血液学和胃肠道不良反应,所有患者均可耐受。结论吉非替尼联合卡铂治疗晚期NSCLC患者的临床疗效优于吉西他滨联合卡铂,其血液学和消化道不良反应发生率低,患者的耐受性较好,是晚期NSCLC患者较为合适的二线治疗方案。
Objective To investigate the clinical efficacy and safety of gefitinib or gemcitabine plus carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods One hundred and fourty-seven patients with advanced NSCLC were randomly divided into two groups. The experimental group was given 71 cases of gefitinib combined with carboplatin and the control group of 66 cases received gemcitabine plus carboplatin. The curative effect and quality of life of two groups of patients were evaluated, and the occurrence of adverse reactions was counted. Results The total effective rates of patients with NSCLC in experimental group and control group were 76.1% and 47.0%, respectively, with statistical significance (P <0.05). The disease control rates were 87.3% and 78.8% respectively (P> 0.05). The median survival time in trial group was 14.5 months, which was significantly different from that in control group (11.8 months) (P <0.05). Adverse reactions in the test group were mainly acne-like rash, diarrhea, nausea, vomiting and loss of appetite. Patients in the control group were predominantly hematological and gastrointestinal adverse reactions, and all patients were tolerated. Conclusion The clinical efficacy of gefitinib combined with carboplatin in the treatment of advanced NSCLC patients is superior to gemcitabine combined with carboplatin, with low incidence of hematological and gastrointestinal adverse reactions and better tolerability in patients with advanced NSCLC, which is more appropriate second-line Treatment programs.